Skip to content

Pharma Mar S.A. Price, Chart & Factor Analysis

Free Data & Analytics Access

Latest earnings: October 29, 2026 results vs estimates

Pharma Mar S.A. · E.PHM.MC · Spain
Use symbol E.PHM.MC in our API & Excel add-in to retrieve this data ↓
65.85
(-0.02%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -100%
Trend -100%
Bubble Risk LOW
Realised Volatility (20D) 25.63%

Pharma Mar S.A. Forecast

Pharma Mar S.A. short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (0 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 25.6% a year, a typical one-standard-deviation range is 63.47–68.23 over a week, 60.98–70.72 over a month and 48.98–82.72 over a year. (Signals as of 4 Nov 2026.)

Pharma Mar S.A. Price Chart

MacroFinance.ai

Pharma Mar S.A. Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Pharma Mar S.A.
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Pharma Mar S.A.
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Pharma Mar S.A.
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for Pharma Mar S.A., red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on Pharma Mar S.A.

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Pharma Mar S.A. Trading Strategies

9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Pharma Mar S.A.; 1 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

Explore all strategies →

Statistical Distribution of Returns

Plus

How Pharma Mar S.A.’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Pharma Mar S.A. behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Pharma Mar S.A. (Spain)

Pharma Mar S.A. is a listed security in Spain. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Pharma Mar S.A.

Frequently asked questions

What is Pharma Mar S.A.?
Pharma Mar S.A. is a listed security in Spain. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Pharma Mar S.A. price?
The latest close is 65.85 (4 Nov 2026), -0.02% on the day. The price at the top of the page refreshes during the trading day.
Is Pharma Mar S.A. in an uptrend?
As of 4 Nov 2026, short-term momentum is strongly negative (0 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly negative (0 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Pharma Mar S.A.?
20-day realised volatility is 25.6% a year (4 Nov 2026), which implies a typical one-standard-deviation move of about 7.4% over a month and 3.6% over a week.
What factors affect Pharma Mar S.A.?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Pharma Mar S.A., grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Pharma Mar S.A.?
9 backtested tactical asset allocation strategies trade Pharma Mar S.A. through VGK; 1 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Pharma Mar S.A. returns analysed?
The Statistical Distribution of Returns section shows the distribution of Pharma Mar S.A. daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Pharma Mar S.A. historical data?
In the Free historical data section of this page: the last 10 years of Pharma Mar S.A. daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Pharma Mar S.A. historical data (last 10 years)

Browse or instantly download the last 10 years of Pharma Mar S.A. daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.PHM.MC&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2057.8
2026-11-1959.2
2026-11-1862.05
2026-11-1764.25
2026-11-1666.6
2026-11-1367.25
2026-11-1268.35
2026-11-1169.3
2026-11-1069
2026-11-0967.4
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma. It also develops LAGOON, which is in Phase III clinical trial for the treatment of small cell lung cancer; SaLuDo, which is in Phase III trial to treat patients with metastatic leiomyosarcoma; as well as PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.